Reports
Sale
Post Traumatic Stress Disorder (PTSD) Market Size, Share: By Treatment Type: Drug Administration, Psychotherapy; By Drug Class: Antidepressants, Anti-Anxiety Drugs, Antipsychotic Drugs, Others; By Patient Type: Children, Adult; By Distribution Channel: Hospital Pharmacies, Others; Regional Analysis; Supplier Landscape; 2024-2032
Post Traumatic Stress Disorder (PTSD) Market Outlook
The post traumatic stress disorder (PTSD) market size in the 7 major markets is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032. The growth of the market can be attributed to the increase in clinical research and the introduction of new and advanced therapies in the market.
Post Traumatic Stress Disorder (PTSD): Introduction
Post traumatic stress disorder (PTSD) is a mental health condition, a stress disorder that can develop post experiencing a terrifying event. Several symptoms include flashbacks/nightmares of similar situations, severe anxiety, uncontrollable thoughts about the event, memory lapses, distorted sense of self, loose control over emotions, hyperarousal, unexplained upset stomach, and sleep disturbances, among others.
Post Traumatic Stress Disorder (PTSD) Market Analysis
Increased clinical research is significantly driving the market growth. New treatment therapies are emerging in the market, exemplified by a new study that claims that patients writing about their trauma in five supervised 30-minute sessions is as effective as the therapies recommended by federal agencies. This therapy has been named written exposure therapy.
Such research studies hold great potential for market growth. The introduction of such effective therapies may create awareness about this stress disorder among more people resulting in increased awareness. Increased awareness is further expected to increase demand for more solutions for this condition and eventually, more research studies, propelling the market growth.
As more effective treatments gain recognition, the increased awareness of the disorder is anticipated to drive a surge in demand for solutions catering to PTSD. This heightened demand, in turn, is expected to stimulate further research initiatives focused on understanding and addressing PTSD, creating a positive feedback loop that would further aid the market growth.
The increased dedication of researchers toward finding effective PTSD treatments is evident in various studies, exemplified by recent research results. The conclusive findings of such studies contribute to the growing body of knowledge surrounding PTSD, fostering a deeper understanding of the condition. The efforts of the research community, coupled with the introduction of innovative therapies, are instrumental in shaping the trajectory of the PTSD market, promising a future marked by increased awareness, advanced treatment options, and sustained growth within the healthcare landscape.
Post Traumatic Stress Disorder (PTSD) Market Segmentations
Market Breakup by Treatment Type
- Drug Administration
- Psychotherapy
Market Breakup by Drug Class
- Antidepressants
- Anti-Anxiety Drugs
- Antipsychotic Drugs
- Others
Market Breakup by Patient Type
- Children
- Adult
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Other Distribution Channels
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Post Traumatic Stress Disorder (PTSD) Market Overview
The prevalence of post traumatic stress disorder (PTSD) is on the rise and is significantly driving the market growth. Increasing stress and adapting to a sedentary lifestyle are the main factors that trigger the occurrence of PTSD in people. According to the National Center for PTSD, 6 out of 10 men (or 60%) and 5 of every 10 women (or 50%) experience at least one trauma in their lifetime. Additionally, the increase in the number of clinical trials is also contributing to the market growth.
To stay ahead of the competition, market players are adopting various competitive strategies, such as mergers and acquisitions, developing new products, and collaborating for research and development. These strategies aim to develop effective antidepressant drugs and ensure the sustainability of market players in the market, bolstering market growth. The market growth is further expected to be driven by the increased awareness about the stress disorder among people.
Post Traumatic Stress Disorder (PTSD) Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Sanofi-aventis Groupe
- Emergent BioSolutions Inc.
- Valneva SE
- GlaxoSmithKline plc.
- Intervet Inc.
- EuBiologics Co., Ltd.
- Astellas Pharma Inc.
- Celldex Therapeutics.
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Marinus Pharmaceuticals, Inc.
- Tonix Pharmaceuticals Holding Corp.
- Greenstone LLC
- Otsuka Pharmaceutical Co., Ltd
- Prometheon Pharma, LLC.
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Drug Class |
|
| Breakup by Patient Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Post Traumatic Stress Disorder (PTSD) Epidemiology Analysis – 7MM
3.1 7MM Epidemiology Scenario Overview (2017-2032)
3.2 United States Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3 EU-4 and United Kingdom Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3.1 Germany Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3.2 France Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3.3 Italy Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3.4 Spain Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3.5 United Kingdom Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.4 Japan Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
4 Post Traumatic Stress Disorder (PTSD) Market Overview – 7MM
4.1 Post Traumatic Stress Disorder (PTSD) Market Historical Value (2017-2023)
4.2 Post Traumatic Stress Disorder (PTSD) Market Forecast Value (2024-2032))
5 Post Traumatic Stress Disorder (PTSD) Market Landscape-7MM
5.1 Post Traumatic Stress Disorder (PTSD) Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Post Traumatic Stress Disorder (PTSD) Product Landscape
5.2.1 Analysis by Diseases Type
5.2.2 Analysis by Treatments
5.2.3 Analysis by Route of Administration
6 Post Traumatic Stress Disorder (PTSD) Treatment Challenges and Unmet Needs
6.1 Treatment Pathway Challenges
6.2 Compliance and Drop-Out Analysis
6.3 Awareness and Prevention Gaps
7 Cost of Treatment
8 Post Traumatic Stress Disorder (PTSD) Market Dynamics
8.1 Market Drivers and Constraints
8.2 SWOT Analysis
8.3 Porter’s Five Forces Model
8.4 Key Demand Indicators
8.5 Key Price Indicators
8.6 Industry Events, Initiatives, and Trends
8.7 Value Chain Analysis
9 Post Traumatic Stress Disorder (PTSD) Market Segmentation -7MM
9.1 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
9.1.1 Market Overview
9.1.2 Drug Administration
9.1.3 Psychotherapy
9.2 Post Traumatic Stress Disorder (PTSD) Market by Drug Class
9.2.1 Market Overview
9.2.2 Antidepressants
9.2.3 Anti-Anxiety Drugs
9.2.4 Antipsychotic Drugs
9.2.5 Others
9.3 Post Traumatic Stress Disorder (PTSD) Market by Patient Type
9.3.1 Market Overview
9.3.2 Children
9.3.3 Adult
9.4 Post Traumatic Stress Disorder (PTSD) Market by Distribution Channel
9.4.1 Market Overview
9.4.2 Hospital Pharmacies
9.4.3 Retail Pharmacies
9.4.4 Other Distribution Channels
9.5 Post Traumatic Stress Disorder (PTSD) Market by Region
9.5.1 Market Overview
9.5.2 United States
9.5.3 EU-4 and the United Kingdom
9.5.3.1 Germany
9.5.3.2 France
9.5.3.3 Italy
9.5.3.4 Spain
9.5.3.5 United Kingdom
9.5.4 Japan
10 United States Post Traumatic Stress Disorder (PTSD) Market
10.1 Post Traumatic Stress Disorder (PTSD) Market Historical Value (2017-2023)
10.2 Post Traumatic Stress Disorder (PTSD) Market Forecast Value (2024-2032)
10.3 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
10.4 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
11 EU-4 and United Kingdom Post Traumatic Stress Disorder (PTSD) Market
11.1 Post Traumatic Stress Disorder (PTSD) Market Historical Value (2017-2023)
11.2 Post Traumatic Stress Disorder (PTSD) Market Forecast Value (2024-2032)
11.3 Germany Post Traumatic Stress Disorder (PTSD) Market Overview
11.3.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
11.3.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
11.4 France Post Traumatic Stress Disorder (PTSD) Market Overview
11.4.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
11.4.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
11.5 Italy Post Traumatic Stress Disorder (PTSD) Market Overview
11.5.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
11.5.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
11.6 Spain Post Traumatic Stress Disorder (PTSD) Market Overview
11.6.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
11.6.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
11.7 United Kingdom Post Traumatic Stress Disorder (PTSD) Market Overview
11.7.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
11.7.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
12 Japan Post Traumatic Stress Disorder (PTSD) Market
12.1 Post Traumatic Stress Disorder (PTSD) Market Historical Value (2017-2023)
12.2 Post Traumatic Stress Disorder (PTSD) Market Forecast Value (2024-2032)
12.2.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
12.2.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
13.3 EU EMA
13.4 INDIA CDSCO
13.5 JAPAN PMDA
13.6 Others
14 Patent Analysis
14.1 Analysis by Type of Patent
14.2 Analysis by Publication year
14.3 Analysis by Issuing Authority
14.4 Analysis by Patent Age
14.5 Analysis by CPC Analysis
14.6 Analysis by Patent Valuation
14.7 Analysis by Key Players
15 Grants Analysis
15.1 Analysis by year
15.2 Analysis by Amount Awarded
15.3 Analysis by Issuing Authority
15.4 Analysis by Grant Application
15.5 Analysis by Funding Institute
15.6 Analysis by NIH Departments
15.7 Analysis by Recipient Organization
16 Clinical Trials Analysis
16.1 Analysis by Trial Registration Year
16.2 Analysis by Trial Status
16.3 Analysis by Trial Phase
16.4 Analysis by Therapeutic Area
16.5 Analysis by Geography
17 Funding and Investment Analysis
17.1 Analysis by Funding Instances
17.2 Analysis by Type of Funding
17.3 Analysis by Funding Amount
17.4 Analysis by Leading Players
17.5 Analysis by Leading Investors
17.6 Analysis by Geography
18 Partnership and Collaborations Analysis
18.1 Analysis by Partnership Instances
18.2 Analysis by Type of Partnership
18.3 Analysis by Leading Players
18.4 Analysis by Geography
19 Supplier Landscape
19.1 Sanofi-aventis Groupe
19.1.1 Financial Analysis
19.1.2 Product Portfolio
19.1.3 Demographic Reach and Achievements
19.1.4 Mergers and Acquisitions
19.1.5 Certifications
19.2 Emergent BioSolutions Inc.
19.2.1 Financial Analysis
19.2.2 Product Portfolio
19.2.3 Demographic Reach and Achievements
19.2.4 Mergers and Acquisitions
19.2.5 Certifications
19.3 Valneva SE
19.3.1 Financial Analysis
19.3.2 Product Portfolio
19.3.3 Demographic Reach and Achievements
19.3.4 Mergers and Acquisitions
19.3.5 Certifications
19.4 GlaxoSmithKline plc.
19.4.1 Financial Analysis
19.4.2 Product Portfolio
19.4.3 Demographic Reach and Achievements
19.4.4 Mergers and Acquisitions
19.4.5 Certifications
19.5 Intervet Inc.
19.5.1 Financial Analysis
19.5.2 Product Portfolio
19.5.3 Demographic Reach and Achievements
19.5.4 Mergers and Acquisitions
19.5.5 Certifications
19.6 EuBiologics Co., Ltd.
19.6.1 Financial Analysis
19.6.2 Product Portfolio
19.6.3 Demographic Reach and Achievements
19.6.4 Mergers and Acquisitions
19.6.5 Certifications
19.7 Astellas Pharma Inc.
19.7.1 Financial Analysis
19.7.2 Product Portfolio
19.7.3 Demographic Reach and Achievements
19.7.4 Mergers and Acquisitions
19.7.5 Certifications
19.8 Celldex Therapeutics.
19.8.1 Financial Analysis
19.8.2 Product Portfolio
19.8.3 Demographic Reach and Achievements
19.8.4 Mergers and Acquisitions
19.8.5 Certifications
19.9 Johnson & Johnson Services Inc.
19.9.1 Financial Analysis
19.9.2 Product Portfolio
19.9.3 Demographic Reach and Achievements
19.9.4 Mergers and Acquisitions
19.9.5 Certifications
19.10 Merck & Co. Inc.
19.10.1 Financial Analysis
19.10.2 Product Portfolio
19.10.3 Demographic Reach and Achievements
19.10.4 Mergers and Acquisitions
19.10.5 Certifications
19.11 Marinus Pharmaceuticals, Inc.
19.11.1 Financial Analysis
19.11.2 Product Portfolio
19.11.3 Demographic Reach and Achievements
19.11.4 Mergers and Acquisitions
19.11.5 Certifications
19.12 Tonix Pharmaceuticals Holding Corp.
19.12.1 Financial Analysis
19.12.2 Product Portfolio
19.12.3 Demographic Reach and Achievements
19.12.4 Mergers and Acquisitions
19.12.5 Certifications
19.13 Greenstone LLC
19.13.1 Financial Analysis
19.13.2 Product Portfolio
19.13.3 Demographic Reach and Achievements
19.13.4 Mergers and Acquisitions
19.13.5 Certifications
19.14 Otsuka Pharmaceutical Co., Ltd
19.14.1 Financial Analysis
19.14.2 Product Portfolio
19.14.3 Demographic Reach and Achievements
19.14.4 Mergers and Acquisitions
19.14.5 Certifications
19.15 Prometheon Pharma, LLC.
19.15.1 Financial Analysis
19.15.2 Product Portfolio
19.15.3 Demographic Reach and Achievements
19.15.4 Mergers and Acquisitions
19.15.5 Certifications
20 Post Traumatic Stress Disorder (PTSD) - Distribution Model (Additional Insight)
20.1 Overview
20.2 Potential Distributors
20.3 Key Parameters for Distribution Partner Assessment
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
22 Company Competitiveness Analysis (Additional Insight)
22.1 Very Small Companies
22.2 Small Companies
22.3 Mid-Sized Companies
22.4 Large Companies
22.5 Very Large Companies
23 Payment Methods (Additional Insight)
23.1 Government Funded
23.2 Private Insurance
23.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032.
The market growth is driven by the increased awareness of the disorder, the expanding healthcare sectors, rising programs and initiatives to spread awareness, and the rising disposable incomes of the patients.
The innovative research studies by doctors to develop new treatment therapies for PTSD is a trend influencing the market growth.
The major regions of the market include United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom.
This situation can be cured with the help of drug administration and psychotherapy.
PTSD can be cured with the help of antidepressants, anti-anxiety drugs, and antipsychotic drugs, among others.
PTSD can affect children as well as adults.
Treatment drugs for PTSD can be availed at hospital pharmacies, retail pharmacies, and other distribution channels.
Key players involved in the market are Sanofi-aventis Groupe, Emergent BioSolutions Inc., Valneva SE, GlaxoSmithKline plc., Intervet Inc., EuBiologics Co., Ltd., Astellas Pharma Inc., Celldex Therapeutics., Johnson & Johnson Services Inc., Merck & Co. Inc., Marinus Pharmaceuticals, Inc., Tonix Pharmaceuticals Holding Corp., Otsuka Pharmaceutical Co., Ltd, Prometheon Pharma, LLC., and Greenstone LLC.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER